Bruker Acquires Canopy Biosciences

Facebook X LinkedIn Email
Bruker Corp. has acquired Canopy Biosciences, a specialist in high multiplex biomarker imaging for immunology, immune-oncology, and cell therapy. The acquisition expands Bruker’s offerings in targeted multiomics and fluorescence-based imaging techniques. Financial details of the transaction have not been disclosed.

Bruker also recently announced the appointment of Bonnie H. Anderson to its board of directors.

Published: September 2020
Fluorescence is a type of luminescence, which is the emission of light by a substance that has absorbed light or other electromagnetic radiation. Specifically, fluorescence involves the absorption of light at one wavelength and the subsequent re-emission of light at a longer wavelength. The emitted light occurs almost instantaneously and ceases when the excitation light source is removed. Key characteristics of fluorescence include: Excitation and emission wavelengths: Fluorescent materials...
A biomarker, short for biological marker, refers to a measurable and quantifiable indicator of a biological condition, process, or response. Biomarkers can be substances or characteristics that are objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacological responses to therapeutic interventions. These markers are often used in medical and scientific contexts to assess health status, diagnose diseases, monitor treatment outcomes,...
BusinessBiophotonicsfluorescenceImagingbiomarkerbiomarker detectionimmunologyoncologymulti-omiccell therapyacquisitionsexpansionRapidScan

We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.